李 昀, 羅學(xué)平, 林繼宗, 黃邵洪, 安 軍, 何錦園, 張軍航△
(1中山大學(xué)附屬第三醫(yī)院心胸外科,廣東 廣州 510630; 2佛山市南海區(qū)人民醫(yī)院心胸外科,廣東 佛山 528200; 3中山大學(xué)附屬第三醫(yī)院肝膽外科,廣東 廣州 510630)
?
PLCE1通過調(diào)控p53抑制肺腺癌A549細(xì)胞凋亡*
李 昀1, 羅學(xué)平2, 林繼宗3, 黃邵洪1, 安 軍1, 何錦園1, 張軍航1△
(1中山大學(xué)附屬第三醫(yī)院心胸外科,廣東 廣州 510630;2佛山市南海區(qū)人民醫(yī)院心胸外科,廣東 佛山 528200;3中山大學(xué)附屬第三醫(yī)院肝膽外科,廣東 廣州 510630)
目的: 探討磷脂酶Cε1(PLCE1)抑制肺腺癌A549細(xì)胞凋亡的作用機(jī)制。方法: 選用人肺腺癌細(xì)胞株A549作為研究對(duì)象。采用real-time PCR和Western blotting法分別檢測PLCE1抑制劑U-73122處理前、后肺腺癌細(xì)胞株A549中PLCE1和p53 mRNA和蛋白水平的表達(dá);流式細(xì)胞術(shù)檢測細(xì)胞凋亡。結(jié)果: 肺腺癌細(xì)胞株A549高表達(dá)PLCE1,低表達(dá)p53;抑制PLCE1表達(dá)后A549細(xì)胞中p53表達(dá)上調(diào),細(xì)胞凋亡明顯增加。結(jié)論: PLCE1通過抑制肺腺癌A549細(xì)胞株中p53的表達(dá),從而抑制A549細(xì)胞凋亡。
肺腺癌; 磷脂酶Cε1; p53; 細(xì)胞凋亡; 甲基化; 表觀遺傳學(xué)
肺癌是我國常見的惡性腫瘤之一,近年來呈逐年上升趨勢,據(jù)中國國家癌癥中心流行病學(xué)調(diào)查研究表明,肺癌發(fā)病率和死亡率已躍居惡性腫瘤第1位[1],但具體發(fā)病機(jī)制尚不明確,治療效果不甚理想,總體生存率偏低。抑癌基因p53表達(dá)降低與多種腫瘤發(fā)生密切相關(guān),包括肺癌[2]。p53可引起細(xì)胞周期阻滯、凋亡及維持基因組穩(wěn)定性從而抑制腫瘤[3],但p53在肺癌中失活的機(jī)制有待進(jìn)一步闡明。
PLCE1基因編碼的磷脂酶Cε1(phospholipids C epsilon 1,PLCE1)是磷脂酶C家族的成員。磷脂酶Cε1可催化磷脂酰肌醇-4,5-二磷酸水解以產(chǎn)生第二信使肌醇1,4,5-三磷酸(inositol 1,4,5-triphosphate,IP3)和二酰基甘油(diacylglycerol,DAG),在細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)過程中起重要作用,調(diào)節(jié)細(xì)胞生長、增殖、分化,影響細(xì)胞骨架改變、細(xì)胞運(yùn)動(dòng)、細(xì)胞凋亡、腫瘤生長及發(fā)展等生物學(xué)行為。
本研究擬通過檢測PLCE1在肺腺癌細(xì)胞株A549中的表達(dá),驗(yàn)證改變PLCE1表達(dá)對(duì)肺腺癌細(xì)胞p53表達(dá)及細(xì)胞功能的影響,初步闡明PLCE1通過p53途徑在肺腺癌細(xì)胞中作用的機(jī)制。
1 材料
PLCE1抗體、p53抗體、兔抗羊及羊抗兔Ⅱ抗、β-actin抗體和PLCE1抑制劑U-73122均購自Santa Cruz;Annexin V試劑盒購自Sigma;DNA純化盒購自Promega;real-time PCR和Western blotting所用試劑均購自Invitrogen;肺腺癌細(xì)胞株A549及對(duì)照細(xì)胞株HEK293均購于中科院上海細(xì)胞庫。
2 方法
2.1 細(xì)胞培養(yǎng) 肺腺癌細(xì)胞株A549及對(duì)照細(xì)胞株HEK293用含10%胎牛血清、2 mmol/L谷氨酰胺、1×105U/L青霉素和0.1 g/L鏈霉素的DMEM細(xì)胞培養(yǎng)液,在CO2培養(yǎng)箱內(nèi)(37 ℃、5% CO2、飽和濕度)連續(xù)培養(yǎng)并傳代。培養(yǎng)液每2~3天換液1次。待克隆細(xì)胞生長至80%融合時(shí),分離擴(kuò)大培養(yǎng)。臺(tái)盼藍(lán)不相容試驗(yàn)檢測細(xì)胞活性,超過98%活性時(shí)方用于下一步實(shí)驗(yàn)。
2.2 實(shí)時(shí)熒光定量PCR TRIzol法提取細(xì)胞總RNA并定量,按試劑盒說明進(jìn)行逆轉(zhuǎn)錄合成cDNA。應(yīng)用實(shí)時(shí)熒光定量PCR儀(MiniOpticon,Bio-Rad上海分公司)檢測,β-actin作為內(nèi)參照。PCR引物:p53上游引物5’- GGAAATCTCACCCCATCCCA-3’,下游引物 5’-CAGTAAGCCAAGATCACGCC-3’;PLCE1上游引物5’-GAGCTGCAATCGAAGTCTGG-3’, 下游引物 5’- AAGGCCTTCTGTGAGTCCTC-3’; β-actin上游引物5’-CTCCATCCTGGCCTCGCTGT-3’, 下游引物 5’-GCTGTCACCTTCACCGTTCC-3’。反應(yīng)體系為20 μL,反應(yīng)條件為95 ℃ 3 min;95 ℃ 10 s,55 ℃ 30 s,39個(gè)循環(huán);并在每個(gè)循環(huán)延伸末端點(diǎn)收集熒光信號(hào),繪制擴(kuò)增曲線,基因的表達(dá)量用2-ΔΔCt表示。
2.3 Western blotting實(shí)驗(yàn) 預(yù)冷PBS洗滌細(xì)胞3次,加入全蛋白裂解液后冰上裂解10 min收集蛋白。將抽提蛋白用BCA法定量后,取50 μg于100 V泳道進(jìn)行SDS-PAGE;電泳結(jié)束后,以90 V、90 min將蛋白轉(zhuǎn)移至PVDF膜; 5% TBS牛奶室溫封閉30 min,孵育I抗羊抗p53(1∶1 000)和兔抗PLCE1 (1∶500)4 ℃過夜,II抗(兔抗羊1∶5 000和羊抗兔1∶2 000)室溫孵育1 h。每次抗體孵育后用Tris緩沖液及聚乙二醇辛基苯基醚(Triton X-100)洗膜。ECL試劑盒進(jìn)行發(fā)光反應(yīng),壓片、顯影、定影,觀察蛋白印跡并進(jìn)行圖像分析。
2.4 細(xì)胞凋亡檢測 根據(jù)試劑盒進(jìn)行操作,收集A549細(xì)胞先用Annexin V染色,再用碘化丙啶 (propidium iodide,PI)5 mg/L,染色15 min。流式細(xì)胞術(shù)檢測細(xì)胞凋亡率,PI+細(xì)胞首先被檢出,Annexin V+細(xì)胞頻數(shù)在剩余細(xì)胞中確定。
3 統(tǒng)計(jì)學(xué)處理
計(jì)量數(shù)據(jù)用均數(shù)±標(biāo)準(zhǔn)差(mean±SD)表示。應(yīng)用統(tǒng)計(jì)學(xué)軟件SPSS 19.0進(jìn)行處理,兩組間比較用Student’st檢驗(yàn)。以P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
1 PLCE1在肺腺癌細(xì)胞中高表達(dá)
采用real-time PCR與Western blotting檢測肺腺癌細(xì)胞株A549中PLCE1的表達(dá),結(jié)果發(fā)現(xiàn),A549細(xì)胞中PLCE1的mRNA和蛋白表達(dá)水平明顯高于正常細(xì)胞HEK293,差異有統(tǒng)計(jì)學(xué)意義(P<0.01),見圖 1。
Figure 1.A549 cells expressed high mRNA(A) and protein (B) levels of PLCE1. Mean±SD. n=30. **P<0.01 vs HEK293.
2 肺腺癌細(xì)胞中p53表達(dá)下調(diào)
本研究檢測了肺腺癌細(xì)胞株A549細(xì)胞中p53的表達(dá),結(jié)果發(fā)現(xiàn),A549細(xì)胞中p53的mRNA和蛋白表達(dá)水平明顯低于正常細(xì)胞HEK293,差異有統(tǒng)計(jì)學(xué)意義(P<0.01),見圖 2。
Figure 2.A549 cells expressed low mRNA(A) and protein (B) levels of p53. Mean±SD. n=30. **P<0.01 vs HEK293.
3 抑制肺腺癌細(xì)胞中PLCE1表達(dá)可促進(jìn)p53表達(dá)
采用PLCE1抑制劑U-73122 (5 mmol/L) 與A549細(xì)胞共培養(yǎng),分別于12 h、24 h及48 h檢測A549細(xì)胞中PLCE1和p53的表達(dá)。結(jié)果發(fā)現(xiàn),抑制A549細(xì)胞中PLCE1的表達(dá)后,p53表達(dá)上調(diào),且p53表達(dá)水平呈明顯的時(shí)間依賴性(P<0.01),見圖 3。
4 抑制PLCE1促進(jìn)肺腺癌細(xì)胞凋亡
采用PLCE1抑制劑U-73122 (5 mmol/L) 與A549細(xì)胞共培養(yǎng),分別于12 h、24 h及48 h檢測A549細(xì)胞凋亡情況。結(jié)果表明,A549細(xì)胞凋亡明顯增加,凋亡率呈明顯的時(shí)間依賴性(P<0.01),見到圖 4。
肺癌是我國最常見的惡性腫瘤[1],其中約85%為非小細(xì)胞肺癌,15%為小細(xì)胞肺癌,非小細(xì)胞肺癌中腺癌為最常見的病理類型。肺癌發(fā)生發(fā)展的分子機(jī)制多樣,研究表明,基因突變、microRNA表達(dá)異常、等位基因高頻率雜合性缺失(LOH)、抑癌基因失活等均可促進(jìn)肺癌的發(fā)生發(fā)展。IPASS研究發(fā)現(xiàn),約有60%的亞裔、女性和非吸煙肺腺癌患者發(fā)生表皮生長因子受體基因突變[4];miRNA-21過表達(dá)可導(dǎo)致肺癌發(fā)生[5];等位基因3p、5q、9p、11p 和17p存在LOH,抑癌基因p53表達(dá)失活,促進(jìn)肺癌發(fā)生[6]。
Figure 3.PLCE1 inhibitor U-73122 (5 mmol/L) upregulated the expression of p53 in A549 cells. A: the bars indicate the levels of PLCE1 mRNA in A549 cells treated with U-73122; B: the immune blots indicate the contents of PLCE1 protein in A549 cells treated with U-73122; C: the bars indicate the levels of p53 mRNA in A549 cells treated with U-73122; D: the immune blots indicate the contents of p53 protein in A549 cells treated with U-73122. ConIgG: isotype IgG used as a control IgG. Mean±SD. n=30. **P<0.01 vs medium group.
Figure 4.Suppression of PLCE1 induced apoptosis of A549 cells. A: the histograms indicate the proportion of apoptotic cells (Annexin V+) treated with U-73122 (5 mmol/L); B: the bars indicate the summarized data of apoptotic cells. mean±SD. n=30. **P<0.01 vs medium group.
磷脂酶Cε1是磷脂酶C家族的成員,在細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)過程中起重要作用。PLCE1可催化磷脂酰肌醇-4,5-二磷酸水解產(chǎn)生第二信使IP3和DAG。IP3和DAG調(diào)節(jié)細(xì)胞生長、增殖、分化,影響細(xì)胞骨架改變、細(xì)胞運(yùn)動(dòng)、細(xì)胞凋亡、腫瘤生長及發(fā)展等生物學(xué)行為[7]。PLCE1由RAS和Rho家族的小GTP酶和由異源三聚體G蛋白調(diào)節(jié),除催化磷脂酰肌醇-4,5-二磷酸水解活性外,還具有1個(gè)鳥嘌呤核苷酸交換活性的N末端結(jié)構(gòu)域。目前已證實(shí)PLCE1與結(jié)直腸癌[8]、膀胱癌[9]及食管癌[10]等多種惡性腫瘤相關(guān),但其在不同類型腫瘤中的表達(dá)情況不盡一致。研究發(fā)現(xiàn),PLCE1在結(jié)直腸癌中表達(dá)下調(diào),被認(rèn)為是結(jié)直腸癌的抑癌基因[8];而膀胱癌及食管癌中PLCE1表達(dá)升高,siRNA抑制PLCE1后,可促進(jìn)p53的表達(dá),同時(shí)促進(jìn)細(xì)胞凋亡[10]。本研究發(fā)現(xiàn)肺腺癌細(xì)胞株A549中PLCE1表達(dá)升高,p53表達(dá)下降,與我們前期研究[11]肺癌患者腫瘤組織中PLCE1和p53的表達(dá)結(jié)果一致。
細(xì)胞凋亡下調(diào)是腫瘤發(fā)生發(fā)展的重要原因,眾多因子參與細(xì)胞凋亡的調(diào)控,如MIF通過激活I(lǐng)L-8,繼而Bcl-2表達(dá)增加從而抑制凋亡[12],TNF-α結(jié)合死亡受體后激活caspase級(jí)聯(lián)反應(yīng)促進(jìn)細(xì)胞凋亡[13],細(xì)胞色素C氧化酶2合成物可誘導(dǎo)p53表達(dá)從而促進(jìn)細(xì)胞凋亡[14]。研究證實(shí),p53與細(xì)胞凋亡密切相關(guān),p53可轉(zhuǎn)錄調(diào)控靶基因,如bax、puma,特異性活化caspase-9和caspase-3/7后上調(diào)Bax/Bcl-2比率,促進(jìn)p53依賴的細(xì)胞凋亡[15]。p53能通過高爾基復(fù)合體轉(zhuǎn)運(yùn)Fas短暫促進(jìn)血管平滑肌細(xì)胞表面Fas表達(dá)并促進(jìn)Fas-FADD的結(jié)合誘導(dǎo)凋亡[16],表明p53對(duì)死亡受體通路和線粒體通路均有影響。通過本研究發(fā)現(xiàn),抑制肺腺癌細(xì)胞中PLCE1的表達(dá)可促進(jìn)p53的表達(dá),進(jìn)而促進(jìn)肺腺癌A549細(xì)胞凋亡。
由此我們推測,PLCE1通過抑制肺腺癌A549細(xì)胞株中p53 的表達(dá),從而抑制細(xì)胞凋亡,PLCE1可能成為肺腺癌治療的新靶點(diǎn)。PLCE1在其它病理類型肺癌中的表達(dá)以及具體作用機(jī)制,有待進(jìn)一步研究證實(shí)。
[1] Chen W, Zheng R, Zhang S, et al. The incidences and mortalities of major cancers in China, 2010[J]. Chin J Cancer, 2014, 33(8):402-405.
[2] Riccardo F, Arigoni M, Buson G, et al. Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers[J]. BMC Genomics, 2014, 15(Suppl 3): S1.
[3] Saha MN, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies[J]. J Hematol Oncol, 2013, 6:23.
[4] Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)[J]. J Clin Oncol, 2011, 29(21):2866-2874.
[5] Xu LF, Wu ZP, Chen Y, et al. MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China[J]. PLoS One, 2014, 9(8):e103698.
[6] Zienolddiny S, Ryberg D, Arab MO, et al. Loss of he-terozygosity is related to p53 mutations and smoking in lung cancer[J]. Br J Cancer, 2001, 84(2):226-231.
[7] Ada-Nguema AS, Xenias H, Hofman JM, et al. The small GTPase R-Ras regulates organization of actin and drives membrane protrusions through the activity of PLCε[J]. J Cell Sci, 2006, 119(Pt 7):1307-1319.
[8] Danielsen SA, Cekaite L, Agesen TH, et al. Phospholipase C isozymes are deregulated in colorectal cancer:insights gained from gene set enrichment analysis of the transcriptome[J]. PLoS One, 2011, 6(9):e24419.
[9] Ou L, Guo Y, Luo C, et al. RNA interference suppres-singPLCE1 gene expression decreases invasive power of human bladder cancer T24 cell line[J]. Cancer Genet Cytogenet, 2010, 200(2):110-119.
[10]Li Y, An J, Huang S, et al. PLCE1 suppresses p53 expression in esophageal cancer cells[J]. Cancer Invest, 2014, 32(6):236-240.
[11]Luo XP. Phospholipase C epsilon-1 inhibits p53 expression in lung cancer[J]. Cell Biochem Funct, 2014, 32(3):294-298.
[12]侯俊娜, 羅益鋒, 王杜娟, 等. siRNA 沉默MIF基因抑制大細(xì)胞肺癌H460細(xì)胞增殖[J].中國病理生理雜志, 2011, 27(5):853-858.
[13]Cisterne A, Baraz R, Khan NI, et al. Silencer of death domains controls cell death through tumour necrosis factor-receptor 1 and caspase-10 in acute lymphoblastic leukemia[J]. PLoS One, 2014, 9(7): e103383.
[14]Stiburek L, Vesela K, Hansikova H, et al. Loss of function of Sco1 and its interaction with cytochromecoxidase[J]. Am J Physiol Cell Physiol, 2009, 296(5):C1218-C1226.
[15]Singh N, Sarkar J, Sashidhara KV, et al. Anti-tumour activity of a novel coumarin-chalcone hybrid is mediated through intrinsic apoptotic pathway by inducing PUMA and altering Bax/Bcl-2 ratio[J]. Apoptosis, 2014, 19(6):1017-1028.
[16]Lahiry L, Saha B, Chakraborty J, et al. Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells[J]. Carcinogenesis, 2010, 31(2):259-268.
PLCE1 suppresses apoptosis of lung adenocarcinoma cells via modulating p53 expression
LI Yun1, LUO Xue-ping2, LIN Ji-zong3, HUANG Shao-hong1, AN Jun1, HE Jin-yuan1, ZHANG Jun-hang1
(1DepartmentofCardiothoracicSurgery,TheThirdAffiliatedHospitalofSunYat-senUniversity,Guangzhou510630,China;2DepartmentofCardiothoracicSurgery,NanhaiPeople’sHospital,Foshan528200,China;3DepartmentofHepatobi-liarySurgery,TheThirdAffiliatedHospitalofSunYat-senUniversity,Guangzhou510630,China.E-mail:yunmao@163.com)
AIM: To investigate the role of phospholipase C epsilon 1 (PLCE1) in modulating the apoptotic mechanism in lung adenocarcinoma A549 cells. METHODS: PLCE1 inhibitor U-73122 was used to suppress the expression of PLCE1. The expression of PLCE1 and p53 in A549 cells was evaluated by quantitative real-time PCR and Western blotting. Apoptosis was assessed by flow cytometry. RESULTS: A549 cells expressed high level of PLCE1 and low level of p53. Inhibition of PLCE1 markedly increased the expression of p53, and increased the apoptosis of A549 cells. CONCLUSION: PLCE1 suppresses apoptosis of A549 cells via inhibiting the expression of p53.
Lung adenocarcinoma; Phospholipase C epsilon 1; p53; Apoptosis; Methylation; Epigenomics
1000- 4718(2015)01- 0119- 05
2014- 08- 22
2014- 11- 12
中山大學(xué)“985”工程項(xiàng)目(No. 82000-31101301)
△通訊作者 Tel: 020-85252230; E-mail: yunmao@163.com
R734.2; R392.11
A
10.3969/j.issn.1000- 4718.2015.01.023